文献速递病毒性肝炎

ACTG 5360 MINMON 试验的依从性视角:慢性丙型肝炎治疗中索磷布韦/维帕他韦 12 周的最小监测方案

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
PubMed 文献 · Clin Infect Dis · 2023-01-01

ACTG A5360 是一项单臂多国临床试验,纳入 5 个国家 400 例初治无失代偿期肝硬化的 HCV 感染者,均接受 12 周索磷布韦/维帕他韦治疗。第 4 周自报最佳依从者 SVR 为 96.5%,亚最佳依从者为 77.8%,两者差异有统计学意义(P < .001)。年龄 <30 岁和美国参与者与早期亚最佳依从独立相关;年龄 <30 岁者早期亚最佳依从的可能性是年长者的 7.1 倍。

要点

  • 第 4 周自报最佳依从者 SVR 为 96.5%,亚最佳依从者为 77.8%(P < .001)。
  • 年龄 <30 岁者早期亚最佳依从可能性是年长者的 7.1 倍。
  • 美国参与者与早期亚最佳依从独立相关。

核心结论

  • 第 4 周自报最佳依从与 SVR 相关;早期自报依从可用于识别治疗失败风险较高者,后者可能从额外支持中获益;年龄 <30 岁者也可优先获得额外依从支持。

研究设计与样本

  • ACTG A5360 为单臂、多国临床试验,从 5 个国家纳入 400 例初治、无失代偿期肝硬化的 HCV 感染者,所有参与者入组时接受 12 周索磷布韦/维帕他韦治疗;399 例启动治疗,395/397(99%)报告在第 24 周完成。

主要发现

  • 第 4 周报告最佳依从的 368 例中 SVR 为 96.5%(95%CI [94.1%, 97.9%]),亚最佳依从者为 77.8%(95%CI [59.2%, 89.4%]),P < .001。
  • 多变量模型中年龄 <30 岁和美国参与者与早期亚最佳依从独立相关;年龄 <30 岁者早期亚最佳依从的可能性是年长者的 7.1 倍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the advent of efficacious oral direct-acting antivirals (DAAs) for hepatitis C virus (HCV), identification of characteristics associated with adherence is critical to treatment success. We examined correlates of sub-optimal adherence to HCV therapy in a single-arm, multinational, clinical trial. METHODS: ACTG A5360 enrolled HCV treatment-naive persons without decompensated cirrhosis from 5 countries. All participants received a 12-weeks course of sofosbuvir/velpatasvir at entry. In-person visits occurred at initiation and week 24, sustained virologic response (SVR) assessment. Adherence at week 4 was collected remotely and was dichotomized optimal (100%, no missed doses) versus sub-optimal (<100%). Correlates of sub-optimal adherence were explored using logistic regression. RESULTS: In total, 400 participants enrolled; 399 initiated treatment; 395/397 (99%) reported completing at week 24. Median age was 47 years with 35% female. Among the 368 reporting optimal adherence at week 4 SVR was 96.5% (95% confidence interval [CI] [94.1%, 97.9%]) vs 77.8% (95% CI [59.2%, 89.4%]) P value < .001. In the multivariate model age <30 years and being a US participant were independently associated with early sub-optimal adherence. Participants <30 years were 7.1 times more likely to have early sub-optimal adherence compared to their older counterparts. CONCLUSIONS: Self-reported optimal adherence at week 4 was associated with SVR. Early self-reported adherence could be used to identify those at higher risk of treatment failure and may benefit from additional support. Younger individuals <30 years may also be prioritized for additional adherence support. Clinical Trials Registration. NCT03512210.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sowah LA, Smeaton L, Brates I, et al. Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment. Clin Infect Dis. 2023. PMID: 36694361. doi:10.1093/cid/ciad034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。